Madrigal Pharmaceuticals vs PTC Therapeutics
MDGL and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDGL and PTCT compare
Madrigal Pharmaceuticals is the larger company, worth 1.9 times as much as PTC Therapeutics ($9.9B against $5.3B).
Madrigal Pharmaceuticals grew revenue faster over the last twelve months (149% versus −35.1% for PTC Therapeutics).
PTC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −9.2% compared with −25.3% at Madrigal Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDGL | PTCT |
|---|---|---|
| Size and price | ||
| Market cap | $9.9B | $5.3B |
| Share price | $427.39 | $63.49 |
| Change, 1 year | −19.2% | −15.3% |
| Change, 5 years | 419% | 58.7% |
| Beta (5Y) | 0.73 | 1.09 |
| Employees | 915 | 991 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.7× | 4.6× (better) |
| P/B | 18.9× | – |
| EV/EBITDA | – | 17.8× |
| P/FCF | – | 2566× |
| FCF yield | −2.1% | 0.04% (better) |
| Fair value | $399.45 | $48.37 |
| Margin of safety | −7.0% (better) | −31.3% |
| Growth | ||
| Revenue growth (TTM) | 149% (better) | −35.1% |
| Revenue growth, 5Y average | – | 35.4% |
| Net income growth (TTM) | – | −114% |
| EPS growth (TTM) | – | −114% |
| Profitability | ||
| Operating margin | −25.1% | 12.8% (better) |
| Net margin | −25.3% | −9.2% (better) |
| FCF margin | −16.1% | 0.18% (better) |
| Return on equity | −53.3% | – |
| Return on invested capital | −1338% | – |
| Financial health | ||
| Debt / equity | 0.65 | – |
| Net debt / EBITDA | – | −7.63 |
| Interest coverage | −10.2× | – |
| Current ratio | 3.20 | 3.27 (better) |
| Altman Z-score | 6.67 (better) | 0.83 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 120% |
| Held by insiders | 27.2% | 3.0% |
| Insider net buying, 12 months | −$33.3M (better) | −$44.2M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 12.7% | 9.6% |
Go deeper
- MDGL stock overview
- MDGL income statement
- MDGL valuation and score
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.